劲方医药2025年报：收入增长24.4%，推进多款RAS疗法临床开发与商业化

Core Viewpoint - The article highlights the significant progress and potential of Jinfang Pharmaceutical in the RAS-targeted therapy market, showcasing its comprehensive pipeline and recent financial performance [2][3]. Financial Performance - For the fiscal year 2025, Jinfang Pharmaceutical reported a revenue of RMB 1.30 billion, representing a year-on-year growth of 24.4%, primarily driven by collaboration and licensing agreements with Verastem regarding GFH375 [2]. - The adjusted net loss (non-IFRS) was RMB 227 million, narrowing by 9.3% compared to the previous year, indicating improved operational efficiency [2]. - As of December 31, 2025, the company had cash reserves of RMB 2.074 billion, providing substantial support for the advancement of its pipeline [2]. Product Pipeline and Clinical Development - Jinfang Pharmaceutical has established one of the most comprehensive RAS-targeted therapy matrices globally, including commercial products like Fluorouracil and clinical-stage candidates such as GFH375 and GFH276 [3]. - The first marketed product, Fluorouracil (GFH925, brand name: Daberu®), received approval in August 2024 and was included in the national medical insurance drug list in 2025 [3]. - GFH375 entered Phase III registration clinical trials in November 2025 for the treatment of metastatic pancreatic cancer, marking it as the first KRAS G12D inhibitor undergoing single-agent registration studies globally [3]. - Clinical data for GFH375 showed an overall response rate (ORR) of 40.7% and a disease control rate (DCR) of 96.7% in pancreatic cancer patients, and an ORR of 57.7% and DCR of 88.5% in non-small cell lung cancer (NSCLC) patients, indicating its potential for best-in-class efficacy [3]. Collaborations and Future Prospects - Verastem has initiated multiple single-agent and combination therapy trials for GFH375/VS-7375, with VS-7375 receiving FDA fast track designation for treating KRAS G12D mutant metastatic pancreatic cancer [4]. - The management indicated that Verastem is optimizing dosing for Western populations to support future registration pathways, with a focus on the first-line combination therapy for GFH375, which is gaining attention overseas [5]. - GFH276's clinical trial application was approved in September 2025, with the first patient enrolled, and initial data showing no severe treatment-related adverse events, validating the pharmacokinetic and tissue distribution advantages of its differentiated molecular structure [5][6].